InvestorsHub Logo
Post# of 252190
Next 10
Followers 833
Posts 119841
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 210461

Wednesday, 04/19/2017 11:39:55 AM

Wednesday, April 19, 2017 11:39:55 AM

Post# of 252190
ENTA—A little more detail re phase-1 trial of EDP-305:

http://finance.yahoo.com/news/enanta-announces-preclinical-data-fxr-102800794.html

EDP-305 is currently in Phase 1 clinical development. Enanta’s ongoing double-blind, placebo-controlled Phase 1a/b study is designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-305 in healthy adults, and in adults with presumptive non-alcoholic fatty liver disease (NAFLD) (obese, with or without pre-diabetes or type 2 diabetes). The study will enroll approximately 150 subjects and is planned to evaluate at least 5 single and multiple dose cohorts, with EDP-305 administered orally, once daily.

I.e. the phase-1a part of the study is in healthy volunteers, and the phase-1b part of the study is in (presumptive) NAFLD patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.